Viva Biotech Holdings (FRA:VB0) LT-Debt-to-Total-Asset: 0.05 (As of Dec. 2025)

What is Viva Biotech Holdings LT-Debt-to-Total-Asset?

Viva Biotech Holdings FRA:VB0 +10.08% 43 LT-Debt-to-Total-Asset is 0.05 as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Viva Biotech Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.05.

Viva Biotech Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.10) to Dec. 2025 (0.05). It may suggest that Viva Biotech Holdings is progressively becoming less dependent on debt to grow their business.

Viva Biotech Holdings (FRA:VB0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Viva Biotech Holdings LT-Debt-to-Total-Asset Related Terms

Viva Biotech Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings LT-Debt-to-Total-Asset Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.30

0.11

0.13

0.10

0.05

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													0.13	0.00	0.10	0.08	0.05

43GF Score

Viva Biotech Holdings FRA:VB0

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Viva Biotech Holdings LT-Debt-to-Total-Asset Calculation

Viva Biotech Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	43.437	/	872.917
	=	0.05

Viva Biotech Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	43.437	/	872.917
	=	0.05

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.05 mean?

Viva Biotech Holdings (FRA:VB0) has a LT-Debt-to-Total-Asset of 0.05 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Viva Biotech Holdings and its competitors.

Is Viva Biotech Holdings' LT-Debt-to-Total-Asset too high?

Viva Biotech Holdings' current LT-Debt-to-Total-Asset is 0.05. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Viva Biotech Holdings' LT-Debt-to-Total-Asset compare to VRTX and REGN?

Viva Biotech Holdings' LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Viva Biotech Holdings stock overvalued right now?

Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 63.8% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current LT-Debt-to-Total-Asset is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.13 is trading 63.8% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

LT-Debt-to-Total-Asset: 0.05
GF Value™: €0.08 vs. price of €0.13 (63.8% above fair value)
GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viva Biotech Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies HKSE:02565 HKSE:02197 HKSE:02410 HKSE:06996 HKSE:01875 HKSE:02480 HKSE:06660 HKSE:01521 HKSE:06955 HKSE:02181 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges VBIZF:USA 01873:Hong Kong

Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website https://www.vivabiotech.com

Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.

43GF Score

Get the complete analysis for FRA:VB0

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13

Price

€0.08

GF Value

View FRA:VB0 Analysis

See LT-Debt-to-Total-Asset data for all stocks →